Adrenocortical insufficiency associated with long-term high-dose fosfestrol therapy for prostatic carcinoma.

Abstract

A 59-year-old man was admitted to our hospital because of muscular pain, weakness, and anorexia. He had been treated with 600 mg/day of fosfestrol, a synthetic estrogen, for 10 years for prostatic carcinoma. Endocrinological studies demonstrated adrenocortical insufficiency due to inadequate ACTH secretion. After initiation of glucocorticoid replacement therapy, his symptoms subsided rapidly. To our knowledge, an association between estrogenic agents, including fosfestrol, and secondary adrenocortical insufficiency has not been previously reported. Physicians who treat patients with long-term and high-dose strong estrogenic agents should be cautious about the possible emergence of secondary adrenocortical insufficiency.

• Authors: H Iida, I Miyamoto, Y Noda, M Sawaki, Y Nagai
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 38 Issue 10 Pg. 804-7 (Oct 1999) ISSN: 0918-2918 [Print] Japan
• PMID: 10526944 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Diethylstilbestrol
• Adrenocorticotropic Hormone
• fosfestrol
• Hydrocortisone

Topics

• Adrenal Insufficiency (chemically induced, metabolism)
• Adrenocorticotropic Hormone (metabolism)
• Antineoplastic Agents (adverse effects, therapeutic use)
• Diethylstilbestrol (adverse effects, analogs & derivatives, therapeutic use)
• Humans
• Hydrocortisone (metabolism)
• Male
• Middle Aged
• Prostatic Neoplasms (drug therapy)